PLUR 最新10-K变化

相对上期新增的文字 · 来源:10-K · 2026-09-10

• We are a biotechnology company leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility and operates in accordance with Good Manufacturing Practice (“GMP”) standards on a self-declared basis. Our platform is designed to en…

• In January 2020, Pluri Biotech established a wholly owned subsidiary, Pluristem GmbH, which is incorporated under the laws of Germany.

• In November 2025, Pluri Biotech established a wholly owned subsidiary, Cellav™, which is incorporated under the laws of the State of Israel.

• Our operations are dedicated to the research, development, manufacturing and commercialization of cell-based products, therapeutics and related technologies across two primary application areas: (i) Human Health and Longevity and (ii) Foodtech and Bio-Farming, as set forth below:

• Our proprietary 3D cell expansion platform is the technological and manufacturing foundation for both business areas, designed to enable scalable, cost-efficient and reproducible production of cell-based products. It uses a synthetic scaffold to create a 3D environment in which adherent or non-adher…

相对上期删除的文字 · 来源:10-K · 2025-09-17

• We are a biotechnology company, leveraging our proprietary cell expansion platform to develop scalable, cell-based solutions across the healthcare, food, and agriculture sectors. Through a collaborative network of ventures, we are advancing a diverse pipeline of products and services, including cult…

• Our operations are dedicated to the research, development and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering innovative solutions across a range of industries, as set forth below:

• We use our advanced cell-based technology platform in the field of regenerative medicine to develop placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, hematologic conditions and, most recently, we have also launched a novel immunotherapy platform.

• PLX cells: Our PLX cells are adherent stromal cells that are expanded using our 3D platform. Our PLX cells can be administered to patients off-the-shelf, without blood or tissue matching or additional manipulation prior to administration. PLX cells are believed to release a range of therapeutic prot…

• In the pharmaceutical area, we have focused on several indications utilizing our product candidates, including, but not limited to, muscle recovery following surgery for hip fracture, incomplete recovery following bone marrow transplantation, critical limb ischemia (“CLI”), chronic Graft versus Host…

相对上期新增的文字 · 来源:10-K · 2026-09-10

• ● our FoodTech endeavors involve significant risks, including the lengthy and complex research and development process associated with cultivated meat, cultivated food and related cell-based food technologies; evolving governmental regulations applicable to cultivated meat, cell-based food products …

• ● our longevity, wellness and aesthetics products may not achieve market acceptance, and we have limited operating and commercialization history in this business. Regulatory uncertainty and the potential for differing product classifications could subject these products to additional requirements an…

• we could fail to regain compliance with Nasdaq Listing Rules and to maintain the listing of our common shares on Nasdaq, which could harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction.

• We maintained discussions with the EIB with the objective of reaching a mutually agreed resolution regarding the EIB Loan. The EIB confirmed that during such discussion period, and while discussions remain ongoing, the EIB is not contemplating any enforcement action, all without prejudice to any of …

• ● Government actions, or other governmental measures limit the movement general populations;

相对上期删除的文字 · 来源:10-K · 2025-09-17

• ● there are risks relating to our food-tech endeavors, including changes in consumer preferences and governmental regulations relating to cultivated meat;

• ● our business and market potential in the field of cultivated food and cell-based coffee technology are unproven, and we have limited insight into trends that may emerge and affect our business;

• ● the research and development associated with technologies for cultivated meat manufacturing is a lengthy and complex process; and

• ● we could fail to maintain compliance with the Audit Committee Requirements (defined below) or to maintain the listing of our common shares on Nasdaq, which could harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction.

• We are currently in advanced discussions with the EIB regarding a potential restructuring of the terms of the EIB Loan, which are currently focused on the new terms of the EIB Loan, including an extension of the current maturity date of the EIB Loan. However, there is no certainty as to the outcome …

相对上期新增的文字 · 来源:10-K · 2026-09-10

• We are a biotechnology company leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility and operates in accordance with GMP standards on a self-declared basis. Our platform is designed to enable scalable, cost-efficient an…

• RESULTS OF OPERATIONS – YEAR ENDED JUNE 30, 2026 COMPARED TO YEAR ENDED JUNE 30, 2025

• Revenues for the year ended June 30, 2026 were $1,016,000, compared to $1,336,000 for the year ended June 30, 2025. The revenues for the years ended June 30, 2026 and 2025, were primarily generated from services provided to CDMO clients for process and product development as well as additional reven…

• Cost of revenues for the year ended June 30, 2026 were $563,000, compared to $682,000 for the year ended June 30, 2025. Cost of revenues includes manufacturing costs related to our CDMO and FoodTech fields, which primary consist of materials, personnel-related and overhead costs. The decrease in cos…

• R&D, net (costs less participation by the IIA, Horizon Europe and the NIAID) increased by 17% from $12,851,000 for the year ended June 30, 2025, to $15,092,000 for the year ended June 30, 2026. The increase was mainly attributable to (1) an increase in salaries and related expenses due to foreign ex…

相对上期删除的文字 · 来源:10-K · 2025-09-17

• We are a biotechnology company, leveraging our proprietary cell expansion platform to develop scalable, cell-based solutions across the healthcare, food, and agriculture sectors. Through a collaborative network of ventures, the Company is advancing a diverse pipeline of products and services, includ…

• We use our advanced cell-based technology platform in the field of regenerative medicine to develop placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, hematologic conditions and, most recently, we have also launched a novel immunotherapy platform.

• In July 2023, we announced that we signed a three-year $4.2 million contract with the NIAID, under which we were to collaborate with the AFRRI and the USUHS, in Maryland, U.S.A., to further advance the development of our PLX-R18 cell therapy as a potential novel treatment for H-ARS, a deadly disease…

• In March 2025, we announced that we entered into an exclusive collaboration agreement with Hemafund, aiming to establish a strategic initiative for stockpiling, local distribution, and potential clinical advancement of our PLX-R18 cell therapy as a countermeasure for H-ARS, in Ukraine. The collabora…

• Immunotherapy MAIT cells: In May 2024, we launched a novel immunotherapy platform utilizing MAIT cells specifically designed to address solid tumors.